Valeant Scores a Rare Win: Have They Turned a Corner?

The video discusses the management change at Valiant, led by CEO Joseph Papa, and the lack of transparency in their operations. Bill Ackman highlights the company's historically strong R&D programs, noting recent drug approvals. Despite these successes, Valiant faces financial challenges due to upcoming genericization and a stretched balance sheet. The company must rely on its existing pipeline, focusing on areas where it already has expertise, rather than pursuing new fields like neurology.

What challenges does Valiant face with its new drugs in relation to genericization?

In what areas is Valiant focusing its research efforts according to the text?